Overview
Chemicals and pharmaceuticals are among the most densely regulated industries in the EU. Beyond the core of chemicals and medicines law – REACH, CLP, marketing authorisation and GMP – companies are hit by almost every horizontal regulation: NIS2, because pharmaceutical companies belong to the health sector and chemical companies to a separate NIS2 sector; CBAM, because fertilisers and hydrogen are CBAM goods; and the sustainability and supply chain rules, because the industry is energy-intensive and sources raw materials worldwide.
Data obligations come on top: clinical trials and pharmacovigilance process health data, and the EHDS creates new access to health data for research and development.
The Most Important Regulations
| Regulation | What it means for chemicals and pharma | Status / key date |
|---|---|---|
| NIS2 | Pharma: Annex I (health); chemicals: Annex II | DE since 06.12.2025, AT since 01.10.2026 |
| CBAM | Imports of fertilisers and hydrogen | Definitive period since 01.01.2026 |
| EUDR | Palm oil, soy and rubber products listed in Annex I | from 30.12.2026 |
| LkSG and CSDDD | Human rights and environment in the supply chain, incl. mercury, POPs and hazardous waste | LkSG since 2023, CSDDD from 26.07.2029 |
| CSRD and EU Taxonomy | Reporting from 1,000 employees and EUR 450 million turnover | Financial year 2027 (report 2028) |
| Product Liability Directive | Easier burden of proof for claimants, no caps | for products from 09.12.2026 |
| EHDS | Pharma as data holder and data user | applicable from 26.03.2027 |
| AI Act | AI in medical devices is high-risk under Annex I | from 02.08.2028 |
| GDPR | Health data from trials and pharmacovigilance | since 25.05.2018 |
| Whistleblower Directive | Internal reporting channel from 50 employees | since 17.12.2023 |
NIS2: Pharma in the Health Sector, Chemicals in Annex II
The classification differs between the two industries:
- Pharma: The health sector (Annex I) includes entities carrying out research and development of medicinal products and manufacturers of basic pharmaceutical products and preparations. Large companies are essential entities (‘particularly important’ in Germany) with proactive supervision and fines of at least EUR 10 million or 2% of worldwide turnover; medium-sized ones are important entities.
- Chemicals: ‘Manufacture, production and distribution of chemicals’ is an Annex II sector. It covers manufacturers and distributors of substances and mixtures within the meaning of REACH and producers of articles made from them. Medium-sized and large companies are important entities.
Medium-sized means at least 50 employees, or more than EUR 10 million turnover and more than EUR 10 million balance sheet total. The obligations – registration, ten minimum measures, reporting of significant incidents within 24 hours, 72 hours and one month – also cover process control systems and laboratory IT.
Chemicals Law as the Foundation
Chemicals law is not covered in detail on this platform, but it shapes many of the other obligations:
- REACH (Regulation (EC) No 1907/2006): registration of substances from 1 tonne per year (‘no data, no market’), authorisation and restriction. Suppliers of articles containing substances of very high concern (SVHC) above 0.1% weight by weight must inform their recipients.
- CLP (Regulation (EC) No 1272/2008): classification, labelling and packaging of hazardous substances and mixtures.
- Cross-links: The simplified DNSH criteria of the EU Taxonomy on pollution prevention concern chemicals in particular. The ecodesign regulation ESPR expressly excludes medicinal products.
Emissions and Raw Materials: CBAM and EUDR
CBAM covers fertilisers and hydrogen, among others. The de minimis threshold of 50 tonnes per year applies to fertilisers; hydrogen is always covered. Importers need authorisation as a CBAM declarant and verified emissions data from their producers, otherwise unfavourable default values apply. Goods originating in Switzerland are exempt.
The EUDR affects the industry through palm oil, soy and rubber and products made from them, insofar as they are listed in Annex I. The delegated act of July 2026 is set to add certain palm oil derivatives – check your customs codes against the version published in the Official Journal.
Supply Chain, Sustainability and Liability
- LkSG: Besides human rights, the LkSG protects environmental positions from three conventions – mercury (Minamata), persistent organic pollutants (Stockholm) and hazardous waste (Basel). For chemicals, these are central risk areas.
- CSRD and EU Taxonomy: After Omnibus I, only companies with more than 1,000 employees and EUR 450 million turnover report. The Taxonomy allows investments in low-emission processes to be shown as taxonomy-aligned.
- Product liability: For products placed on the market after 9 December 2026, disclosure rights and presumptions in favour of claimants apply. German pharmaceutical liability under § 84 AMG remains as a special liability regime.
Data and AI: GDPR, EHDS, AI Act
Health data is a special category under the GDPR. The EHDS makes pharmaceutical companies data holders that provide certain data via the access body, and gives them access as data users to health data for research and AI training – mostly from 26 March 2029. Under the AI Act, AI in medical devices and in vitro diagnostics is high-risk under Annex I (from 2 August 2028).
Deadlines 2026/2027
| Date | What applies |
|---|---|
| since 01.10.2026 | NISG 2026 in Austria; registration by end of 2026 |
| 09.12.2026 | Transposition deadline of the Product Liability Directive |
| 30.12.2026 | EUDR for medium-sized and large companies |
| 01.02.2027 | CBAM certificates go on sale |
| 19.03.2027 | Transposition deadline for the CSRD changes from the Omnibus |
| 26.03.2027 | EHDS generally applicable |
| 30.09.2027 | First annual CBAM declaration for 2026 |
| 02.12.2027 | AI Act: high-risk AI under Annex III |
| 02.08.2028 | AI Act: AI in products under Annex I, e.g. medical devices |
| 26.03.2029 | EHDS: most rules on secondary use |
DACH Specifics
- Germany: NIS2 has applied since 6 December 2025, with registration at the BSI. The Bundestag passed the transposition of the Product Liability Directive on 8 October 2026; promulgation is pending. The LkSG continues to apply until it is reformed.
- Austria: NISG 2026 since 1 October 2026. As of October 2026, there was no ministerial draft for the new product liability rules. There is no supply chain act.
- Switzerland: CBAM exemption for goods of Swiss origin. Operators of critical infrastructure – including in health – must report cyberattacks to the BACS within 24 hours. For REACH registration of substances supplied to the EU, Swiss manufacturers need an only representative in the EU or an EU importer.
Checklist
- Clarify NIS2 classification per entity: health sector (Annex I) or chemicals (Annex II)
- Include process control systems, laboratory IT and service providers in risk management
- Record CBAM imports of fertilisers and hydrogen and request emissions data
- Check palm oil, soy and rubber products against EUDR Annex I
- Extend the LkSG risk analysis to mercury, POPs and hazardous waste
- Review data protection concepts for trial and pharmacovigilance data with the EHDS in mind
- Combine the whistleblowing system and the LkSG complaints procedure
Find out which regulations apply to your company with the regulation finder.